Skip to main content

Day: August 23, 2022

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) — GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2022 and gave updates on its business. Second Quarter 2022 Financial Highlights Cash position Cash was $265.4 million as of June 30, 2022, compared to $276.8 million as of December 31, 2021. We believe that our existing cash will be sufficient for us to fund our operating expenses and capital expenditure requirements into 2025. Research and development expenses R&D expenses were $4.2 million for the quarter ended June 30, 2022, compared to $2.0 million for the same quarter in 2021. The increase was primarily due to increased activities relating to our...

Continue reading

BOS Reports Second Quarter of the Year 2022 Financial Results

Growth of 12% in Revenues as compared to Second Quarter of 2021 RISHON LE ZION, Israel, Aug. 23, 2022 (GLOBE NEWSWIRE) — BOS Better Online Solutions Ltd. (“BOS” or the “Company”) (NASDAQ: BOSC) reported its financial results for the second quarter of the year 2022. Revenues for the second quarter of 2022 grew by 12% to $10.3 million from $9.2 million in the comparable quarter last year. Gross profit margin for the second quarter of 2022 improved to 21.4%, compared to 17.3% in the comparable quarter last year. Operating profit for the second quarter grew by 315% to $537,000 compared to an operating profit of $129,000 in the comparable quarter last year. EBITDA for the second quarter increased to $652,000 from $207,000 in the comparable quarter last year. Financial expenses for the second quarter of 2022 increased...

Continue reading

GDS Holdings Limited Reports Second Quarter 2022 Results

SHANGHAI, China, Aug. 23, 2022 (GLOBE NEWSWIRE) — GDS Holdings Limited (“GDS Holdings”, “GDS” or the “Company”) (NASDAQ: GDS; HKEX: 9698), a leading developer and operator of high-performance data centers in China, today announced its unaudited financial results for the second quarter ended June 30, 2022. Second Quarter 2022 Financial HighlightsNet revenue increased by 24.0% year-over-year (“Y-o-Y”) to RMB2,310.4 million (US$344.9 million) in the second quarter of 2022 (2Q2021: RMB1,863.9 million). Service revenue increased by 23.6% Y-o-Y to RMB2,302.7 million (US$343.8 million) in the second quarter of 2022 (2Q2021: RMB1,863.0 million). Net loss was RMB375.3 million (US$56.0 million) in the second quarter of 2022 (2Q2021: net loss of RMB298.5 million). Adjusted EBITDA (non-GAAP) increased by 18.6% Y-o-Y to RMB1,062.2 million...

Continue reading

KANZHUN LIMITED Announces Second Quarter 2022 Financial Results

BEIJING, Aug. 23, 2022 (GLOBE NEWSWIRE) — KANZHUN LIMITED (“BOSS Zhipin” or the “Company”) (Nasdaq: BZ), a leading online recruitment platform in China, today announced its unaudited financial results for the second quarter ended June 30, 2022. Second Quarter 2022 HighlightsRevenues for the second quarter of 2022 were RMB1,112.3 million (US$166.1 million), a decrease of 4.8% from RMB1,168.2 million for the same quarter of 2021. Calculated cash billings1 for the second quarter of 2022 were RMB979.2 million (US$146.2 million), a decrease of 32.2% from RMB1,444.5 million for the same quarter of 2021. Average monthly active users2 for the second quarter of 2022 were 26.5 million, a decrease of 12.8% from 30.4 million for the same quarter of 2021. Total paid enterprise customers3 in the twelve months ended June 30, 2022 increased...

Continue reading

Plus Therapeutics to Present Data from ReSPECT-GBM™ Clinical Trial at the European Society for Medical Oncology Congress 2022

AUSTIN, Texas, Aug. 23, 2022 (GLOBE NEWSWIRE) — Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing innovative, targeted radiotherapeutics for rare and difficult-to-treat cancers, today announced it will present data from the Phase 1/2a ReSPECT-GBM™ dose escalation clinical trial evaluating the Company’s lead investigational targeted radiotherapeutic, Rhenium-186 NanoLiposome (186RNL), in recurrent glioblastoma in an oral presentation at the European Society for Medical Oncology (ESMO) Congress 2022, being held September 9-13, 2022 in Paris, France. Details of the oral presentation:Title 277O: The ReSPECT-GBM™ Phase I/IIa Dose Escalation Trial of Rhenium-186 NanoLiposome (186RNL) in Recurrent Glioma via Convection Enhanced Delivery (CED) & Planned Phase IIb TrialDate September...

Continue reading

Anavex Life Sciences Reports New Publication in Medical Journal Highlighting the Relevance of SIGMAR1 Activation to Compensate for Early Alzheimer’s Disease

Mechanism of Action of ANAVEX®2-73 (blarcamesine) and ANAVEX®3-71 (AF710B) is the activation of SIGMAR1 Endogenous increase in SIGMAR1 activation as a compensatory mechanism against early Alzheimer’s disease Top line results of randomized, placebo-controlled Phase 2b/3 study ANAVEX®2-73-AD-004 for the treatment of early Alzheimer’s disease are expected in the fall of 2022 NEW YORK, Aug. 23, 2022 (GLOBE NEWSWIRE) — Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders, including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, and other central nervous system (CNS) diseases, today reported a relevant new peer-reviewed...

Continue reading

Outdoor Power Equipment Market Size to Hit USD 43.24 Billion by 2029 | Exhibit a CAGR of 5.3%

Increasing Lawn and Garden Care to Propel Growth of Global Outdoor Power Equipment IndustryOutdoor Power Equipment Market Share Outdoor Power Equipment Market SharePune, India, Aug. 23, 2022 (GLOBE NEWSWIRE) — According to Fortune Business Insights, the global outdoor power equipment market size is projected to hit USD 43.24 billion by 2029 and exhibit a CAGR of 5.3% during the forecast period. The market size stood at USD 28.61 billion in 2021 and USD 30.04 billion in 2022. The rising adoption of industry 4.0 and increasing lawn and garden care are expected to boost the market growth, states Fortune Business Insights in its report titled Outdoor Power Equipment Market Outlook 2022-2029. Major Players Announce Novel Products to Expand Product Portfolio Prominent companies operating in the market announce novel products to expand...

Continue reading

Testing, Inspection & Certification (TIC) Market Size to Outstrip $379.89Bn, Globally, by 2027 at 5.2% CAGR, Global Analysis by The Insight Partners

The testing, inspection, certification market size expected to grow from $252.30 billion in 2019 to $379.89 billion by 2027; it is estimated to grow at a CAGR of 5.2% from 2019 to 2027. New York, Aug. 23, 2022 (GLOBE NEWSWIRE) — The Insight Partners published latest research study on “Testing, Inspection & Certification Market to 2027 – Global Analysis and Forecasts by Sourcing Type (In-House service and Outsourced Services); Service Type (Testing, Inspection, and Certification); and End-User (Food & Beverage, Healthcare & Pharmaceutical, Consumer Goods & Retail, Energy & Power, Manufacturing & Construction, and Others)”, the global testing, inspection, certification market growth is driven by rise in adoption of technology enabled TIC solutions by market players & continuous technological...

Continue reading

JD.com Announces Second Quarter and Interim 2022 Results

BEIJING, Aug. 23, 2022 (GLOBE NEWSWIRE) — JD.com, Inc. (NASDAQ: JD and HKEX: 9618), a leading supply chain-based technology and service provider, today announced its unaudited financial results for the three and six months ended June 30, 2022. Second Quarter 2022 HighlightsNet revenues for the second quarter of 2022 were RMB267.6 billion (US$140.0 billion), an increase of 5.4% from the second quarter of 2021. Net service revenues for the second quarter of 2022 were RMB41.6 billion (US$6.2 billion), an increase of 21.9% from the second quarter of 2021. Income from operations for the second quarter of 2022 was RMB3.8 billion (US$0.6 billion), compared to RMB0.3 billion for the same period last year. Non-GAAP2 income from operations was RMB5.8 billion (US$0.9 billion) for the second quarter of 2022, as compared to RMB2.5 billion...

Continue reading

InvestmentPitch Media Video Discusses Black Tusk Resources’ Application for Drill Permits for both its PG Highway and MoGold Projects Located North of Val d’Or, Quebec

VANCOUVER, British Columbia, Aug. 23, 2022 (GLOBE NEWSWIRE) — Black Tusk Resources (CSE:TUSK) (OTCPink:BTKRF) (FSE:0NB) has applied for drill permits for both its PG Highway and MoGold projects located north of Val d’Or, Quebec. Black Tusk’s MoGold and PG Highway projects are comprised of adjoining claims covering 2,400 hectares. The company currently holds 100% ownership in 6 separate gold and palladium projects in the Abitibi greenstone belt region of Canada. A Media Snippet accompanying this announcement is available by clicking on the image or link below:For more information, please view the InvestmentPitch Media video which provides additional information about this news and the company. The video is available for viewing on “InvestmentPitch” and on “YouTube”. If these links are not enabled, please visit www.InvestmentPitch.com...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.